Expanding the CRISPR Toolbox
The CRISPR-Cas9 system is best known for its ability to knock out or replace specific genes, via targeted cleavage of the genome. But scientists are developing many more applications, typically by using an inactive Cas9 to target other enzymes to specific genomic sites. From transcriptional regulation to base editing, these developments are extending the range of biological questions that can be probed with CRISPR/Cas9.
View the animation on CRISPR gene editing and beyond.
View the poster on expanding the CRISPR toolbox.
This Collection is editorially independent, produced with financial support from a third party. About this content.
Horizon Discovery Group plc (LSE: HZD) ("Horizon") drives the application of gene editing and gene modulation within the global life science market – supporting scientists on the path from research to therapy.
Built upon more than a decade of experience in the engineering of cell lines, Horizon offers an unmatched portfolio of tools and services to help scientists gain a greater understanding of gene function, identify genetic drivers behind human disease, deliver biotherapeutics, cellular and gene therapies for precision medicine as well as develop and validate diagnostic workflows.
Horizon’s solutions enable almost any gene to be altered, or its function modulated, in human and other mammalian cell lines.
The Company’s customers include many of the world’s foremost academic institutes, global pharmaceutical and biotechnology companies as well as clinical diagnostic laboratories. Insight into the challenges faced by these organizations enables the company to focus efforts on development of innovative solutions that not only differentiate the company’s offering, but also fuel development of the next wave of precision medicines.
Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.
